SUPERNUS PHARMACEUTICALS holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 1,738,482 | $56,935,286 | 0.82% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 1, 2025 |
| June 30, 2025 | 1,581,093 | $49,836,051 | 0.66% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | July 30, 2025 |
| Sept. 30, 2025 | 1,345,402 | $64,296,762 | 0.83% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Oct. 28, 2025 |
| Dec. 31, 2025 | 1,406,522 | $69,904,143 | 0.91% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 5, 2026 |
| March 31, 2026 | 1,351,331 | $69,850,299 | 0.96% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | April 28, 2026 |
| June 30, 2026 | 1,485,821 | $69,105,535 | 0.74% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | July 29, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
No verified related disclosures are included in this freeze.
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.